Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy
Posted inDiabetes & Endocrinology news

Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy

In a large retrospective cohort, women who discontinued GLP‑1 receptor agonists shortly before or during early pregnancy had greater gestational weight gain and higher risks of preterm birth, gestational diabetes, and hypertensive disorders compared with propensity‑matched unexposed pregnancies.
Targeting Mitochondria: A Practical Algorithm for Diabetes Care in Maternally Inherited Diabetes and Deafness (MIDD)
Posted inDiabetes & Endocrinology news

Targeting Mitochondria: A Practical Algorithm for Diabetes Care in Maternally Inherited Diabetes and Deafness (MIDD)

Maternally inherited diabetes and deafness (MIDD) is driven by m.3243A>G mitochondrial mutation with mixed β‑cell failure and insulin resistance. GLP‑1 receptor agonists and SGLT2 inhibitors have biologic plausibility and cardiorenal benefits in MIDD; we propose a pathophysiology‑driven treatment algorithm and practical monitoring guidance.
Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context
Posted inClinical Updates Diabetes & Endocrinology Specialties

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.
Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial
Posted inDiabetes & Endocrinology Specialties

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial

This review synthesizes evidence from a multicentre, phase 3 trial on ecnoglutide, demonstrating significant and sustained weight loss in overweight/obese adults without diabetes, with a favorable safety profile, supporting its clinical use in weight management.